v3.26.1
Shareholders' Equity
12 Months Ended
May 02, 2026
Share-Based Payment Arrangement [Abstract]  
Shareholders' Equity

Note 13. Shareholders’ Equity

Share buyback programs

On March 31, 2021, as subsequently amended on June 16, 2022, the Board of Directors authorized the purchase of up to $200.0 million of the Company’s outstanding common stock through June 14, 2024 (the “2021 Buyback Authorization”). On June 13, 2024, the Board of Directors authorized a new share buyback authorization, that commenced on June 17, 2024, for the purchase of up to $200.0 million (the “2024 Buyback Authorization”) of the Company’s outstanding common stock which expired on June 17, 2026. Purchases could have been made in private transactions or on the open market, including pursuant to purchase plans designed to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. We did not make any purchases under the 2024 Buyback Authorization.

The following table summarizes the activity under the 2021 Buyback Authorization:

 

 

Fiscal Year Ended

 

 

 

May 2, 2026

 

 

May 3, 2025

 

 

April 27, 2024

 

Shares purchased

 

 

 

 

 

136,000

 

 

 

627,586

 

Average price per share

 

$

 

 

$

11.55

 

 

$

21.93

 

Total cost (in millions)

 

$

 

 

$

1.6

 

 

$

13.8

 

Prior to its expiration, a total of 3,553,961 shares were purchased under the 2021 Buyback Program at a total cost of $134.6 million. All purchased shares were retired and are reflected as a reduction of common stock for the par value of shares, with the excess applied as a reduction to retained earnings. No further shares can be purchased under the 2021 Buyback Authorization. As of May 2, 2026, prior to its expiration, the dollar value of shares that remained available to be purchased by the Company under the 2024 Buyback Program was $200.0 million.

Dividends

The Company paid dividends totaling $8.3 million, $20.4 million, and $19.9 million in fiscal 2026, fiscal 2025, and fiscal 2024, respectively. Dividends paid in fiscal 2026 and fiscal 2025 include $0.5 million and $0.9 million, respectively, of dividend equivalent payments for restricted stock units that vested.

Accumulated other comprehensive income (loss)

Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. A summary of changes in accumulated other comprehensive income (loss), net of tax is shown below:

(in millions)

 

Currency translation adjustments (1)

 

 

Derivative
instruments

 

 

Total

 

Balance as of April 29, 2023

 

$

(19.8

)

 

$

0.8

 

 

$

(19.0

)

Other comprehensive income (loss)

 

 

(18.1

)

 

 

(1.3

)

 

 

(19.4

)

Tax (expense) benefit

 

 

1.4

 

 

 

0.3

 

 

 

1.7

 

Net current period other comprehensive income (loss)

 

 

(16.7

)

 

 

(1.0

)

 

 

(17.7

)

Balance as of April 27, 2024

 

 

(36.5

)

 

 

(0.2

)

 

 

(36.7

)

Other comprehensive income (loss)

 

 

9.7

 

 

 

(1.8

)

 

 

7.9

 

Tax (expense) benefit

 

 

(1.4

)

 

 

0.4

 

 

 

(1.0

)

Net current period other comprehensive income (loss)

 

 

8.3

 

 

 

(1.4

)

 

 

6.9

 

Balance as of May 3, 2025

 

 

(28.2

)

 

 

(1.6

)

 

 

(29.8

)

Other comprehensive income (loss)

 

 

18.1

 

 

 

4.0

 

 

 

22.1

 

Tax (expense) benefit

 

 

(0.2

)

 

 

(0.9

)

 

 

(1.1

)

Net current period other comprehensive income (loss)

 

 

17.9

 

 

 

3.1

 

 

 

21.0

 

Balance as of May 2, 2026

 

$

(10.3

)

 

$

1.5

 

 

$

(8.8

)

 

 

 

 

 

 

 

 

 

 

(1) Includes foreign currency gains and losses related to debt designated as a net investment hedge. See Note 8, "Derivative Financial Instruments and Hedging Activities" for additional information.

 

Stock-based compensation

The Company has granted stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), performance stock units (“PSUs”) and stock awards to employees and non-employee directors under the Methode Electronics, Inc. 2022 Omnibus Incentive Plan (“2022 Plan”), the Methode Electronics, Inc. 2014 Omnibus Incentive Plan (“2014 Plan”) and the Methode Electronics, Inc. 2010 Stock Plan (“2010 Plan”). The Company’s stockholders approved the 2022 Plan on September 14, 2022. The Company can no longer make grants under the 2014 Plan and 2010 Plan.

Subject to adjustment as provided in the 2022 Plan and the 2022 Plan’s share counting provisions, the number of shares of the Company’s common stock that are available for all awards under the 2022 Plan is 5,550,000, less one share for every one share of common stock subject to an option or SAR award granted after April 30, 2022 under the 2014 Plan and 2.28 shares for every one share that was subject to an award other than an option or SAR granted after April 30, 2022 under the 2014 Plan. As of May 2, 2026, there were approximately 0.9 million shares available for award under the 2022 Plan.

Stock-based compensation expense

All stock-based payments to employees and directors are recognized in selling and administrative expenses on the consolidated statements of operations. Awards subject to graded vesting are recognized using the accelerated recognition method over the requisite service period. The table below summarizes the stock-based compensation expense related to the equity awards:

 

 

Fiscal Year Ended

 

 

 

May 2, 2026

 

 

May 3, 2025

 

 

April 27, 2024

 

(in millions)

 

(52 Weeks)

 

 

(53 Weeks)

 

 

(52 Weeks)

 

RSUs

 

$

5.1

 

 

$

5.2

 

 

$

2.0

 

PSUs

 

 

2.5

 

 

 

0.7

 

 

 

 

Deferred non-employee director awards

 

 

0.4

 

 

 

0.9

 

 

 

1.0

 

Non-employee director awards

 

 

0.5

 

 

 

0.6

 

 

 

0.6

 

Total stock-based compensation expense

 

$

8.5

 

 

$

7.4

 

 

$

3.6

 

 

Restricted stock awards (RSAs)

Prior to May 2, 2026, the Company had certain RSAs outstanding which were subject to the achievement of an EBITDA measure for fiscal 2025. The following table summarizes the RSA activity:

 

 

 

Restricted
stock
awards

 

 

Weighted
average grant
date fair value

 

Non-vested at April 29, 2023

 

 

933,674

 

 

$

28.73

 

Awarded

 

 

 

 

$

 

Vested

 

 

 

 

$

 

Forfeited

 

 

(144,000

)

 

$

28.28

 

Non-vested at April 27, 2024

 

 

789,674

 

 

$

28.81

 

Awarded

 

 

 

 

$

 

Vested

 

 

 

 

$

 

Forfeited

 

 

(79,325

)

 

$

28.28

 

Non-vested at May 3, 2025

 

 

710,349

 

 

$

28.87

 

Awarded

 

 

 

 

$

 

Vested

 

 

 

 

$

 

Forfeited

 

 

(710,349

)

 

$

 

Non-vested at May 2, 2026

 

 

 

 

$

 

The EBITDA performance measure for fiscal 2025 was not met and the outstanding RSAs were cancelled in June 2025. No RSAs remain outstanding as of May 2, 2026.

 

Restricted stock units (RSUs)

RSUs granted vest over a pre-determined period of time, up to five years from the date of grant. The fair value of the RSUs granted are based on the closing stock price on the date of grant and earn dividend equivalents during the vesting periods, which are forfeitable if the RSUs don’t vest. The following table summarizes RSU activity:

 

 

 

Restricted
stock
units

 

 

Weighted
average grant
date fair value

 

Non-vested at April 29, 2023

 

 

770,667

 

 

$

30.47

 

Awarded

 

 

389,966

 

 

$

21.48

 

Vested

 

 

(36,221

)

 

$

42.72

 

Forfeited

 

 

(182,772

)

 

$

29.65

 

Non-vested at April 27, 2024

 

 

941,640

 

 

$

26.43

 

Awarded

 

 

441,353

 

 

$

11.09

 

Conversion of cash bonus to RSUs

 

 

160,401

 

 

$

12.87

 

Vested

 

 

(735,309

)

 

$

24.28

 

Forfeited

 

 

(187,535

)

 

$

22.71

 

Non-vested at May 3, 2025

 

 

620,550

 

 

$

15.31

 

Awarded

 

 

999,450

 

 

$

6.61

 

Vested

 

 

(340,459

)

 

$

17.23

 

Forfeited

 

 

(82,228

)

 

$

12.86

 

Non-vested at May 2, 2026

 

 

1,197,313

 

 

$

7.67

 

 

In July 2024, 160,401 RSUs were awarded in exchange for cash bonuses earned by certain employees. These RSUs vested in March 2025. As the expense associated with the cash bonuses was previously recognized in fiscal 2024, there was no incremental expense to be recognized for these RSUs. The Company reclassified $2.1 million from accrued employee liabilities to additional paid-in capital on its consolidated balance sheets related to the conversion of the cash bonuses to RSUs.

As of May 3, 2025, there were 147,329 RSUs that vested for which shares were issued in the first quarter of fiscal 2026. As of May 2, 2026, unrecognized share-based compensation expense for RSUs was $4.5 million which will be recognized over a weighted-average amortization period of 1.4 years.

Performance stock units (PSUs)

In fiscal 2025, the Company granted 208,661 PSUs which will vest upon the achievement of a total stockholder return (“TSR”) measure based on the growth in the Company’s stock price over a three-year performance period that ends April 29, 2028. In fiscal 2026, the Company granted 835,479 PSUs. The number of shares to be issued may range from 0% to a maximum of 200% of the PSUs granted. The Company estimated the grant date fair value of the PSUs using the Monte Carlo simulation model, as the TSR metric and changes in stock price are considered market conditions under ASC 718. The following table provides a summary of the weighted-average assumptions for the PSUs granted:

 

 

Assumptions

 

Expected volatility

 

 

66.34

%

Risk free interest rate

 

 

3.68

%

Expected term (in years)

 

 

2.72

 

Grant date fair value

 

$

7.99

 

 

The PSUs earn dividend equivalents during the vesting periods, which are forfeitable if the PSUs do not vest. As of May 2, 2026, unrecognized share-based compensation expense for the PSUs was $4.9 million, which is expected to be recognized over a weighted average period of approximately 1.9 years. The following table summarizes PSU activity:

 

 

Performance
stock
units

 

 

Weighted
average grant
date fair value

 

Non-vested at April 27, 2024

 

 

 

 

$

 

Awarded

 

 

208,661

 

 

$

14.09

 

Vested

 

 

 

 

$

 

Forfeited

 

 

 

 

$

 

Non-vested at May 3, 2025

 

 

208,661

 

 

$

14.09

 

Awarded

 

 

835,479

 

 

$

7.11

 

Vested

 

 

 

 

$

 

Forfeited

 

 

(30,878

)

 

$

7.27

 

Non-vested at May 2, 2026

 

 

1,013,262

 

 

$

8.33

 

 

Non-employee director stock awards

The Company previously granted stock awards to its non-employee directors as a component of their compensation. The stock awards vested immediately upon grant. Non-employee directors could have elected to defer receipt of their shares under the Company’s non-qualified deferred compensation plan. The following table summarizes awards granted to non-employee directors:

 

 

 

Non-employee director awards

 

 

Deferred non-employee director awards

 

 

Total

 

 

Weighted
average grant
date fair value

 

Outstanding at April 29, 2023

 

 

 

 

 

45,750

 

 

 

45,750

 

 

$

40.56

 

Awarded

 

 

16,804

 

 

 

31,569

 

 

 

48,373

 

 

$

32.72

 

Issued

 

 

(16,804

)

 

 

 

 

 

(16,804

)

 

$

33.33

 

Outstanding at April 27, 2024

 

 

 

 

 

77,319

 

 

 

77,319

 

 

$

37.23

 

Awarded

 

 

56,680

 

 

 

93,749

 

 

 

150,429

 

 

$

9.86

 

Issued

 

 

(56,680

)

 

 

(23,756

)

 

 

(80,436

)

 

$

10.49

 

Outstanding at May 3, 2025

 

 

 

 

 

147,312

 

 

 

147,312

 

 

$

22.39

 

Awarded

 

 

55,629

 

 

 

61,051

 

 

 

116,680

 

 

$

7.54

 

Issued

 

 

(55,629

)

 

 

(11,140

)

 

 

(66,769

)

 

$

10.33

 

Outstanding at May 2, 2026

 

 

 

 

 

197,223

 

 

 

197,223

 

 

$

18.80

 

During the third quarter of fiscal year 2026, the Company terminated its deferred compensation plan and it is expected to be fully liquidated by January 2027.

Stock options

The following table summarizes stock option activity:

 

 

Stock Options

 

 

Weighted average exercise price

 

 

Weighted average life (years)

 

 

Aggregate intrinsic value (in millions)

 

Outstanding at April 29, 2023

 

 

20,000

 

 

$

37.01

 

 

 

1.2

 

 

$

0.1

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(12,000

)

 

$

37.01

 

 

 

 

 

 

 

Outstanding at April 27, 2024

 

 

8,000

 

 

$

37.01

 

 

 

0.2

 

 

$

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(8,000

)

 

$

37.01

 

 

 

 

 

 

 

Outstanding at May 3, 2025

 

 

 

 

 

 

 

 

 

 

$

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Forfeited

 

 

 

 

$

 

 

 

 

 

$

 

Outstanding at May 2, 2026